DC
AARD

Decheng Capital’s Aardvark Therapeutics AARD Stock Holding History

Decheng Capital’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8M Hold
3,917,299
– – 2.23% 5
2025
Q4 		$51.4M Hold
3,917,299
– – 6.92% 4
2025
Q3 		$52.1M Hold
3,917,299
– – 9.08% 4
2025
Q2 		$53M Hold
3,917,299
– – 13.38% 2
2025
Q1 		$29.4M Buy
+3,917,299
New +$44M 8.25% 3

Other funds holding AARD

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Decheng Capital's AARD Position: Q1 2026 in Review

Decheng Capital held its Aardvark Therapeutics (AARD) position steady in Q1 2026 at 3,917,299 shares worth $14.8M. The position accounts for 2.23% of the portfolio, ranked #5.

Decheng Capital first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $53M in Q2 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Decheng Capital held 3,917,299 shares of Aardvark Therapeutics worth $14.8M as of Q1 2026.
  • Decheng Capital left its Aardvark Therapeutics share count unchanged in Q1 2026.
  • Aardvark Therapeutics made up 2.23% of Decheng Capital's portfolio in Q1 2026, its #5 holding.
  • Decheng Capital first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Decheng Capital's Aardvark Therapeutics position peaked at $53M in Q2 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Decheng Capital's 13F filing for Q1 2026, filed 13 May 2026.